ARCHIVES

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

This article is from The Cancer Letter archive.

Vol. 28 No. 04 | January 25, 2002

Download PDF Visit The Full Archive

Related Articles

Budget Projections for 1978 Offer Clues On Research NCI Hopes To Fund

June 18, 1976

Federal Budget Cuts Implemented March 1; HHS Agencies Grapple with Consequences

March 8, 2013

In Brief: Robert Bast Succeeds Singleton As Director Of Duke Cancer Center; Robert Bell Deputy

August 14, 1987

Latest U.S. cancer statistics cover 84% of population.

December 5, 2003

FDA Rile Changes Reporting Requirements for Adverse Events

November 18, 1994

In Brief: Congresswomen Receive FASEB Awards for Public Service for Support of NIH

May 2, 1997